{
    "clinical_study": {
        "@rank": "4783", 
        "arm_group": [
            {
                "arm_group_label": "Ecopipam", 
                "arm_group_type": "Experimental", 
                "description": "Active substance being tested"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Inactive substance being tested"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research study is to gather scientific information about the\n      effectiveness and safety of the study drug, Ecopipam (PSYRX 101), for the treatment of\n      self-injurious behaviors when compared with the effectiveness and safety of placebo\n      (inactive substance) in subjects with Lesch-Nyhan Disease."
        }, 
        "brief_title": "Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lesch-Nyhan Disease", 
            "Self-injurious Behavior"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lesch-Nyhan Syndrome", 
                "Self-Injurious Behavior"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be done in approximately 6 centers in approximately 4 countries, and\n      approximately 24 subjects will be included.  This study is divided into two parts.  The\n      first is a double-blinded portion lasting up to 18 weeks in total.  The second portion is an\n      optional open-label extension and lasts up to 54 weeks total.  The total duration of the\n      study, if you choose to participate in both portions, is anticipated to be up to\n      approximately 78 weeks.\n\n      The first portion of this study is double-blind and assignment to a treatment group is done\n      randomly.  In this study, there are two treatment groups.  One group will receive Ecopipam\n      for one 6-week period and placebo for two 6-week periods, and the other group will receive\n      Ecopipam for two 6-week periods and placebo for one 6-week period.\n\n      Subjects who did not experience any clinically significant side effects during the blinded\n      portion of the study may be eligible to participate in an open-label extension that may last\n      up to 54 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have classic LND as defined by (a) characteristic clinical syndrome\n             (evidence of overproduction of uric acid, severe generalized dystonia, frequent and\n             persistent self-injurious behavior (SIB), and cognitive impairment) and (b)\n             laboratory confirmation for mutation of the HPRT gene or severe deficiency of the\n             associated enzyme.\n\n          -  Subjects must have a minimum combined score of 20 on the Behavior Problems Inventory\n             (BPI) SIB subscales for frequency and severity as assessed by the caregiver.\n\n          -  Subjects must have a minimum score of 4 on the Physician's Global Impression (PGI)\n             severity scale.\n\n          -  Subject must be \u2265 6 years old.\n\n          -  Subjects must weigh > 10 kg.\n\n        Exclusion Criteria:\n\n          -  Subjects who are currently treated with medications for seizures.\n\n          -  Subjects who are on neuroleptics or dopamine-depleting agents.\n\n          -  Subjects with impaired renal function as defined by a serum creatinine >1.5 mg/dL."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01751802", 
            "org_study_id": "PSY102"
        }, 
        "intervention": {
            "arm_group_label": "Ecopipam", 
            "description": "Antagonist of the dopamine D1 receptor", 
            "intervention_name": "Ecopipam", 
            "intervention_type": "Drug", 
            "other_name": [
                "PSYRX 101", 
                "SCH 39166"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Sch 39166"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lesch Nyhan Disease", 
            "Self-Injury"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "link": {
            "description": "Sponsor's website", 
            "url": "http://www.psyadonrx.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "H.J. Jinnah"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario La Paz"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease", 
        "other_outcome": {
            "description": "An additional objective of the study is to assess the safety of ecopipam in subjects with LND for up to 52 weeks.", 
            "measure": "Safety of ecopipam in patients with Lesch-Nyhan Disease", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks"
        }, 
        "overall_official": {
            "affiliation": "Emory University", 
            "last_name": "H J Jinnah, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the BPI (SIB subscales - total for frequency and severity) as assessed by the caregiver.", 
            "measure": "Behavior Problems Inventory - Self-Injurious Behavior Subscale", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01751802"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary objectives of this study are to assess the effect of withdrawal and maintenance of ecopipam's effects in subjects with LND.", 
            "measure": "Behavior Problems Inventory", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "source": "Psyadon Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Psyadon Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013", 
        "why_stopped": "Study terminated for commercial reasons"
    }
}